Insights

Practical perspectives on German MedTech market entry.

Concrete, healthcare-specific thinking on reimbursement, KOL engagement, distributor development, clinical evidence and commercial execution in Germany.

Market Access6 min read

Reimbursement is the gate, not the finish line

Why German reimbursement strategy must be designed before — not after — your clinical evidence plan, and how it shapes pricing and adoption.

Read insight
Distribution7 min read

Why most distributor relationships underperform in Germany

The structural reasons international MedTech companies lose traction with German distributors — and how qualification and performance management fix it.

Read insight
KOL Development5 min read

KOL engagement is not a contact list

Building clinical credibility in Germany means structured validation with the physicians who decide adoption — not collecting names.

Read insight
Commercial Execution6 min read

Strategy is useful. Execution creates value.

Why the gap between a German market-entry strategy and commercial results is where most MedTech companies stall — and how local execution closes it.

Read insight
Clinical Evidence8 min read

Real-world evidence that supports reimbursement

How PMCF and real-world evidence programmes connect commercial adoption to the evidence payers and hospitals actually require in Germany.

Read insight
Fix Germany6 min read

Diagnosing an underperforming German market

A structured way to identify why adoption and revenue are below expectation — and the go-to-market reset that rebuilds traction.

Read insight

Want perspective on your German opportunity?